Non-small-cell lung cancer (NSCLC) treated with chemotherapy: Survival analysis of 50 patients

被引：0
|
作者：
Flores, MM [1 ]
Murillo, SM [1 ]
Alonso, EG [1 ]
Gilart, AB [1 ]
CarcellerVidal, JA [1 ]
机构：
[1] HOSP ARNAU VILANOVA,LLEIDA,SPAIN
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1088 / 1088
页数：1
相关论文
共 50 条
  • [1] Genetic analysis of cytidine deaminase (CDA) for the prediction of response to chemotherapy and survival in advanced non-small-cell lung cancer (NSCLC) patients treated with gemcitabine
    Vasile, Enrico
    Giovannetti, Elisa
    Tibaldi, Carmelo
    Mey, Valentina
    Nannizzi, Sara
    Stasi, Irene
    Danesi, Romano
    Del Tacca, Mario
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 256 - 256
  • [2] INDIVIDUALIZED CHEMOTHERAPY (CT) IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Obodnikov, Oleksandr O.
    Orlovsriy, Oleksiy A.
    Parshikov, Oleksandr V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1280 - S1281
  • [3] Retrospective analysis of a group of patients with advanced Non-Small-Cell lung cancer (NSCLC) treated with Gefitinib
    Bandera, M.
    Bascialla, L.
    Martinelli, B.
    Masera, G. L. Rodolfo
    Vallini, I.
    Zanlorenzi, L.
    Pinotti, G.
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 25 - 25
  • [4] Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib
    McGrath, Alexandria C.
    Sandhu, Geeta
    Walpole, Euan
    McCaffrey, Elizabeth
    Hollingworth, Samantha A.
    [J]. ANTI-CANCER DRUGS, 2018, 29 (08) : 786 - 790
  • [5] Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
    M Satouchi
    S Negoro
    Y Funada
    Y Urata
    T Shimada
    S Yoshimura
    Y Kotani
    T Sakuma
    H Watanabe
    S Adachi
    Y Takada
    Y Yatabe
    T Mitsudomi
    [J]. British Journal of Cancer, 2007, 96 : 1191 - 1196
  • [6] Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
    Satouchi, M.
    Negoro, S.
    Funada, Y.
    Urata, Y.
    Shimada, T.
    Yoshimura, S.
    Kotani, Y.
    Sakuma, T.
    Watanabe, H.
    Adachi, S.
    Takada, Y.
    Yatabe, Y.
    Mitsudomi, T.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (08) : 1191 - 1196
  • [7] EGFR mutation and response to chemotherapy in non-small-cell lung cancer (NSCLC) patients.
    Lee, KH
    Han, SW
    Jeong, S
    Kim, DW
    Chung, DH
    Im, SA
    Kim, TY
    Heo, DS
    Bang, YJ
    Kim, NK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 641S - 641S
  • [8] Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Preoperative Chemotherapy
    Deng, L.
    Jiang, C.
    Perimbeti, S.
    Chen, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S234 - S234
  • [9] A cost utility analysis of erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC)
    Bradbury, P. A.
    Jang, R.
    Isogai, P.
    Mittmann, N.
    Evans, W.
    Shepherd, F. A.
    Leighl, N. B.
    Ng, R.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A72 - A72
  • [10] NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Brahmer, Julie R.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott J.
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, Stephen
    Snzol, Mario
    Harbison, Christopher T.
    Kollia, Gerogia D.
    Gupta, Ashok
    Gettinger, Scott N.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 157 - 157
12345